Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 8-(isoindolin-2-ylmethyl)-2,9-dihydro-3h-pyridazino(3,4,5-de)quinazolin-3-one
2. E-7449
3. E7449
4. Parp Inhibitor 2x-121
5. Stenoparib
1. 1140964-99-3
2. E7449
3. E-7449
4. Stenoparib
5. Parp Inhibitor 2x-121
6. Unii-9x5a2qia7c
7. 9x5a2qia7c
8. Cid 25267262
9. 2x-121
10. 11-(1,3-dihydroisoindol-2-ylmethyl)-2,3,10,12-tetrazatricyclo[7.3.1.05,13]trideca-1(12),5(13),6,8,10-pentaen-4-one
11. 3h-pyridazino(3,4,5-de)quinazolin-3-one, 8-((1,3-dihydro-2h-isoindol-2-yl)methyl)-1,2-dihydro-
12. Stenoparib [who-dd]
13. Schembl3886731
14. Chembl3644587
15. Schembl22023558
16. Bcp19934
17. Ex-a1282
18. Nsc783107
19. Nsc798215
20. S8419
21. Zinc59277233
22. Ccg-267668
23. Cs-3479
24. Nsc-783107
25. Nsc-798215
26. Sb16888
27. 8-(1,3-dihydro-isoindol-2-ylmethyl)-2,9-dihydro-1,2,7,9-tetraaza-phenalen-3-one
28. Ac-36842
29. Hy-12418
30. A909458
31. Q27273339
32. 8-(isoindolin-2-ylmethyl)-2,9-dihydro-3h-pyridazino[3,4,5-de]quinazolin-3-one
| Molecular Weight | 317.3 g/mol |
|---|---|
| Molecular Formula | C18H15N5O |
| XLogP3 | 1.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 317.12766012 g/mol |
| Monoisotopic Mass | 317.12766012 g/mol |
| Topological Polar Surface Area | 69.1 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 586 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Stenoparib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Stenoparib, including repackagers and relabelers. The FDA regulates Stenoparib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Stenoparib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Stenoparib supplier is an individual or a company that provides Stenoparib active pharmaceutical ingredient (API) or Stenoparib finished formulations upon request. The Stenoparib suppliers may include Stenoparib API manufacturers, exporters, distributors and traders.
Stenoparib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Stenoparib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Stenoparib GMP manufacturer or Stenoparib GMP API supplier for your needs.
A Stenoparib CoA (Certificate of Analysis) is a formal document that attests to Stenoparib's compliance with Stenoparib specifications and serves as a tool for batch-level quality control.
Stenoparib CoA mostly includes findings from lab analyses of a specific batch. For each Stenoparib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Stenoparib may be tested according to a variety of international standards, such as European Pharmacopoeia (Stenoparib EP), Stenoparib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Stenoparib USP).
LOOKING FOR A SUPPLIER?
